Canagliflozin improves HF symptoms: CHIEF-HF

canagliflozin improves hf symptoms chief hf

Sumary of Canagliflozin improves HF symptoms: CHIEF-HF:

  • LBS.05. Building on the Foundations of Treatment: Advances in Heart Failure Therapy.
  • Presented at: American Heart Association Scientific Sessions;
  • Disclosures: The CHIEF-HF trial was sponsored by Janssen Scientific Affairs.
  • Spertus reports receiving grant support from Abbott Vascular, the American College of Cardiology Foundation, Janssen and Myokardia;
  • Back to Healio The SGLT2 inhibitor canagliflozin improved HF symptoms within 3 months in patients with HF, regardless of ejection fraction or diabetes status, according to results of the fully remote CHIEF-HF trial.
  • Lauer Endowed Chair in Metabolism and Vascular Disease Research at the University of Missouri-Kansas City School of Medicine, said during a press conference at the American Heart Association Scientific Sessions.
  • Participants were able to complete the trial without a single face-to-face visit by utilizing the self-report Kansas City Cardiomyopathy Questionnaire (KCCQ) on their smartphone.
  • Participating sites screened electronic medical records to identify patients with HF;

Want to know more click here go to source.

From -


Site Language

By continuing to use the site, you agree to the use of cookies. more information

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.